Trial Profile
Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NIVOSQUACS
- 01 Sep 2023 Results (n=31) reporting safety and efficacy data published in the Journal of the European Academy of Dermatology and Venereology
- 23 Jan 2023 Planned number of patients changed from 31 to 61.
- 23 Jan 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2027.